title: Localized amyloidosis: a survey of 35 French cases.
abstract: Since the prognosis of localized amyloidosis remains unclear, we conducted a survey to define the characteristics and the course of this disease. The charts of 35 patients with either laryngeal (14 patients), tracheobronchial (10 patients), colonic (1 patient), or lower urinary tract amyloidosis (10 patients) were analyzed. The average age at diagnosis was 52.7+/-12 years (range 33-73 years). The amyloid protein type was specified to be amyloid light chain (AL) in 15 cases. All patients had undergone additional biopsies (accessory salivary glands, rectal, fat pad and bone marrow aspirates) to rule out a systemic disease. Symptomatic treatments included endoscopic excision and laser therapy. Colchicine and chemotherapy with prednisone and melphalan were prescribed with limited success. During a mean follow-up period of 6.1+/-5.3 years no patient developed a systemic form of amyloidosis. Six deaths were reported, one related to the disease because of a fatal airway hemorrhage. We suggest that immunolabeling studies should be more routinely performed. There was no risk of developing a systemic disease from local amyloid deposits in our survey. However, local evolution can be life-threatening. Such patients should be referred to specialist centers for further evaluation. Management requires close follow-up to exclude recurrence and to determine the appropriate symptomatic treatment.
authors.affiliation: Department of Internal Medicine, Hôpital Jean Bernard, BP 577, 86021, Poitiers cedex, France. m.paccalin@chu-poiters.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Paccalin
authors.forename: Eric
authors.initials: E
authors.lastname: Hachulla
authors.forename: Claire
authors.initials: C
authors.lastname: Cazalet
authors.forename: Leila
authors.initials: L
authors.lastname: Tricot
authors.forename: Miguel
authors.initials: M
authors.lastname: Carreiro
authors.forename: Mathieu
authors.initials: M
authors.lastname: Rubi
authors.forename: Gilles
authors.initials: G
authors.lastname: Grateau
authors.forename: Pascal
authors.initials: P
authors.lastname: Roblot
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D016022:Case-Control Studies; D003078:Colchicine / Q000627:therapeutic use; D003106:Colon / Q000378:metabolism / Q000473:pathology; D003625:Data Collection; D004724:Endoscopy / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010789:Phototherapy / Q000379:methods; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012137:Respiratory System / Q000378:metabolism / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D006074:Gout Suppressants; D007147:Immunoglobulin Light Chains; D008558:Melphalan; D003078:Colchicine; D011241:Prednisone